- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04002284
Anlotinib in Metastatic HER2 Negative Breast Cancer
The Efficacy and Safety of Anlotinib in Metastatic HER2 Negative Breast Cancer, a Single Arm Phase II Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Breast cancer is one of the most common malignant tumors in women, which is a serious threat to women's health. Despite the continuous improvement of treatment, 30% of breast cancer eventually develops into advanced breast cancer. The median survival of advanced breast cancer after routine treatment is 2-3 years. The main treatments include chemotherapy, endocrine therapy, and targeted therapy. The treatment of metastatic breast cancer (MBC) aims to improve quality of life, reduce pain and prolong survival.
Angiogenesis plays an important role in tumor cell proliferation and metastasis. Various anti-angiogenic drugs such as bevacizumab, sunitinib, sorafenib, etc. have been developed and widely used in various tumors. Treatments such as colon cancer, lung cancer, and renal cell carcinoma significantly improve PFS and OS in patients with advanced disease, and the adverse reactions are well tolerated. However, anti-angiogenic therapy has certain limitations in the treatment of advanced breast cancer.
Anrotinib hydrochloride capsule is a new drug independently developed in China. It is a multi-target receptor tyrosine kinase inhibitor targeting angiogenesis-related kinases such as VEGFR1/2/3, FGFR1/2/3 and other kinases such as cell growth-related kinases such as PDGFRα/β, c-Kit, and Ret , and it was approved by China Food and Drug Administation for the treatment of patients with locally advanced or metastatic non-small cell lung cancer who have progressed or relapsed after receiving at least 2 systemic chemotherapy. Basic research shows that anlotinib is effective in breast cancer cell lines, but lacks the results of clinical application of advanced breast cancer. This study is based on the results of phase I clinical trials of allerinib in a variety of advanced solid tumors, to explore its efficacy and safety in HER2-negative advanced breast cancer.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100021
- National Cacner Center/ Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 18 and 75 year-old women; Pathologically or cytologically confirmed breast cancer; HER2 negative(immunohistochemistry or fluorescence in situ hybridization);
- ECOG score: 0-1, expected survival time ≥ 3months;
- Anthracycline- / taxane- pretreated (adjuvant, neoadjuvant) breast cancer patients who have failed from 1-2 standard chemotherapies after recurrence and metastasis;
- According to RECIST 1.1, exist at least ≥1 measurable lesion(CT >1cm,other examination >2cm);
- The patients have enough organ function. The laboratory test indexes must comply with the following requirements:
Blood routine: neutrophil≥1.5G/L, platelet count ≥80G/L, hemoglobin ≥90g/L Liver function: serum bilirubin ≤ 1.5 times the upper limit of normal value; ALT and AST≤2.5 times the upper limit of normal value; ALT and AST≤5 times the upper limit of normal value when liver metastasis Renal function: serum creatinine ≤ 1.0times the upper limit of normal value, creatinine clearance >50ml/min(Cockcroft-Gault formula)
- Women of child-bearing age should be carried out pregnancy test (serum or urine) within 7 days before recruit, the results should be negative; and are willing to adopt the appropriate methods of contraception during the trial and 8 weeks after last administration;
- Can swallow oral drugs;
- The patients have good compliance to the therapy and follow-up to be scheduled and are able to understand the study protocol and sign the Informed Consent Form.
Exclusion Criteria:
- The patients in pregnancy or lactation growth period and did not take effective contraception;
- The patients who received ≥3 chemotherapies(Do not include endocrine therapy)after recurrence and metastasis; involved in other clinical trials four weeks prior to the start of the study;
- The patients with a variety of factors that affect the oral administration and absorption of drugs;
- The patients with rapid progression of viscera invasion(liver lesion >1/2 viscera area or liver dysfunction);
- The patients have uncontrollable mental illness.
- The patients who had serious adverse effect to oral etoposide or were allergic to etoposide.
- The patients who have only bone metastasis without other measurable lesion;
- The patients experience severe cardiovascular diseases;
- The patients experience severe upper gastrointestinal ulcer or malabsorption syndrome.
- Abnormal bone marrow functions(neutrophil<1.5G/L, platelet count <75G/L, hemoglobin <90g/L);
- Abnormal renal function(serum creatinine > 1.5 times the upper limit of normal value);
- Abnormal liver function(serum bilirubin ≤ 1.5 times the upper limit of normal value);
- The patients have uncontrollable brain metastasis;
- The patients do not have good compliance to the therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: anlotinib
anlotinib 12mg qd p.o. d1-14/21day/cycle
|
Anlotinib 12mg p.o. d1-14, 21days/cycle
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
objective response rate(ORR)
Time Frame: through study completion, an average of 1 year
|
Objective response rate defined as confirmed complete response or partial response under RECIST 1.1 criteria.
CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD.
To be assigned a status of CR or PR, changes in tumor measurements must be confirmed by repeat assessments performed no fewer than 4 weeks after the response criteria are first met.
|
through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
disease control rate(DCR)
Time Frame: through study completion, an average of 1 year
|
Number of participants with stable disease or partial response or complete response treating by anloitnib according to RESIST criteria v1.1.
|
through study completion, an average of 1 year
|
Progression free survival (PFS)
Time Frame: From date of enrollment until the date of first documented progression, assessed up to 24 months
|
Progression-free survival estimated using Kaplan-Meier methods is defined as the time from the date of informed consent to the earlier of death or disease progression.
Patients alive without disease progression are censored at the date of last disease evaluation.
Progressive disease (PD) based on RECIST 1.1 is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Equivocal progression of non-target lesions also qualifies as PD.
|
From date of enrollment until the date of first documented progression, assessed up to 24 months
|
overall survival(OS)
Time Frame: From date of enrollment until death, assessed up to 24 months
|
OS, defined as the time from the date of informed consent until to the date of death, regardless of the cause of death.
|
From date of enrollment until death, assessed up to 24 months
|
Safety and Tolerability
Time Frame: through study completion, an average of 1 year
|
All the treatment-related adverse events occurred as assessed by CTCAE v4.0
|
through study completion, an average of 1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
circulating tumor DNA biomarker
Time Frame: From date of enrollment until the date of first documented progression, assessed up to 24 months
|
biomarkers measurement in dynamic circulating tumor DNA sequencing on the day of enrollment and at the end of every two cycle (28 days one cycle)
|
From date of enrollment until the date of first documented progression, assessed up to 24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCC1692
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasm
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...Not yet recruitingBreast Cancer | Neoplasm, Breast | Malignant Neoplasm of Breast | Breast Tumor | Mammary Cancer | Mammary Neoplasms, Human | Tumor, Breast | Mammary NeoplasmUnited States
-
National Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Triple-Negative Breast CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterU.S. Army Medical Research and Development Command; U.S. Army Medical Research...CompletedBreast Carcinoma | Malignant Breast Neoplasm | Benign Breast NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | HER2-Positive Breast CarcinomaUnited States
-
Indiana UniversityIndiana University HealthCompletedBreast Cancer | Breast Neoplasms | Anxiety | Breast Carcinoma | Fear | Cancer of Breast | Malignant Tumor of Breast | Malignant Neoplasm of Breast | Mammary Cancer | Human Mammary Carcinoma | Mammary Neoplasm, Human | Mammary Carcinoma | Neoplasm Remission, Spontaneous | Spontaneous Neoplasm Regression | Regression,... and other conditionsUnited States
-
National Cancer Institute, ThailandCompleted
-
Umbria Bioengineering TechnologiesToscana Life Sciences Sviluppo s.r.l.; London South Bank University; ELAROS 24... and other collaboratorsRecruitingWomen's Health: Neoplasm of BreastItaly, Spain, Poland, Portugal, Switzerland
-
Istanbul Aydın UniversityActive, not recruiting
-
University of OviedoCompletedWomen's Health: Neoplasm of BreastSpain
-
National Cancer Institute, ThailandCompleted
Clinical Trials on Anlotinib Hydrochloride
-
First People's Hospital of HangzhouChia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRecurrent High-grade GliomaChina
-
Peking Union Medical College HospitalRecruitingPheochromocytoma | ParagangliomaChina
-
Peking Union Medical College HospitalRecruitingParaganglioma, Extra-Adrenal | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma | Pheochromocytoma, Metastatic | Paraganglioma, MalignantChina
-
Sun Yat-sen UniversityChia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
First Hospital of Shijiazhuang CityUnknownCarcinoma | Small Cell Lung Cancer | Lung NeoplasmChina
-
First Hospital of Shijiazhuang CityUnknownCarcinoma | Non-small Cell Lung Cancer | Lung NeoplasmChina
-
Peking Union Medical College HospitalRecruiting
-
Sun Yat-sen UniversityRecruitingSarcoma,Soft TissueChina
-
Peking University Third HospitalNot yet recruitingNon-Small Cell Lung Cancer
-
Cancer Institute and Hospital, Chinese Academy...RecruitingAnlotinib | Sarcoma,Soft Tissue | Trunk | Extremity | Intensity-modulated Radiotherapy | Major Wound ComplicationsChina